Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced the appointment of Gail K. Boudreaux to its Board of Directors.

“We are delighted to welcome Gail to Novavax’ Board,” said Stanley C. Erck, President and CEO of Novavax. “Her outstanding leadership and business experience will be important to our continued growth and success. Gail’s insight on health payors will be particularly important as we continue to move towards commercialization of our vaccines.”

Ms. Boudreaux most recently served as the Executive Vice President of UnitedHealth Group from May 2008 until February 2015 and was the Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014. Her extensive experience includes more than 30 years of service across a broad spectrum of health care operations. Ms. Boudreaux is currently a director of Zimmer Holdings, Inc. and Xcel Energy Inc. and a trustee of Dartmouth College. Ms. Boudreaux holds a Master of Business Administration degree in finance and health care administration from the Columbia Business School and a bachelor’s degree in psychology from Dartmouth College. She has been honored as one of Fortune’s 50 Most Powerful Women in American Business for the last six years and was recognized by Modern Healthcare as one of the Top 25 Women in Healthcare.

“I am very happy to be joining Novavax at such an exciting time,” said Ms. Boudreaux. “I look forward to helping the company achieve its goal to develop and deliver safe and effective vaccines to improve global heath.” (Original Source)

Shares of Novavax closed yesterday at $9.13 . NVAX has a 1-year high of $9.95 and a 1-year low of $3.92. The stock’s 50-day moving average is $8.62 and its 200-day moving average is $7.88.

On the ratings front, Novavax has been the subject of a number of recent research reports. In a report issued on April 9, MLV & Co. analyst Vernon Bernardino maintained a Buy rating on NVAX, with a price target of $14, which represents a potential upside of 53.3% from where the stock is currently trading. Separately, on March 27, Citigroup’s Joel Beatty assigned a Buy rating to the stock and has a price target of $10.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Joel Beatty have a total average return of -0.8% and 58.5% respectively. Bernardino has a success rate of 46.8% and is ranked #2895 out of 3632 analysts, while Beatty has a success rate of 100.0% and is ranked #2055.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.